BETH ISRAEL DEACONESS MEDICAL CENTER, INC.

• TRIAD NATIONAL SECURITY, LLC

  UEI X7WUS5LRBQU3

  $4M

  Subcontractor to this prime · 2 sub-awards · latest Mar 10, 2025

  • Department of Energy
  • “BETH ISRAEL DEACONNESS MEDICAL CENTER (BIDMC) - STANDALONE - ITEM LEVEL - EMPLOYEE BENEFITS, BUSINESS INSURANCE AND ANCILLARY SERVICES (PENSION, RETIREE MEDICAL, ACTUARIAL, ETC.)”
  • “RAPTER-BETH ISRAEL DEACONESS MEDICAL-STANDALONE-ITEM LEVEL-DESIGN AND CONSTRUCTION SERVICES”
• SEATTLE CHILDREN'S HOSPITAL

  UEI SZ32VTCXM799

  $651.4K

  Subcontractor to this prime · 2 sub-awards · latest Nov 25, 2025

  • National Institutes of Health
  • “STATEMENT OF WORK – YEAR 7 (BASE) – BAROUCH LAB DURING THE PRECEDING YEARS OF THE AWARD, WE FOCUSED ON DEVELOPING AN INNOVATIVE AND PHYSIOLOGICALLY RELEVANT MOUSE CHALLENGE MODEL THAT UNDERGOES REPEATED ULTRA-LOW DOSE MTB EXPOSURES TO ASSESS THE PROTECTIVE EFFICACY OF TB VACCINES. IN YEAR 6, WE SUCCESSFULLY ESTABLISHED AND VALIDATED A HIGHLY REPRODUCIBLE MURINE REPEATED ULTRA-LOW DOSE CHALLENGE MODEL WITH REDUCED STRINGENCY. USING THIS MODEL, WE TESTED THE PROTECTIVE EFFICACY OF BCGS AND ΔLPRG VACCINES. UNDER THE REPEATED ULTRA-LOW DOSE EXPOSURE MODEL, ΔLPRG IMMUNIZATION CONFERRED ~65% PROTECTION AGAINST ACQUISITION OF INFECTION, COMPARED WITH ~45% PROTECTION OBSERVED WITH THE SINGLE ULTRA-LOW DOSE CHALLENGE, REPRESENTING A SIGNIFICANT IMPROVEMENT IN VACCINE-INDUCED PROTECTION. WE ALSO EXPANDED OUR CORRELATES OF PROTECTION ANALYSES TO IDENTIFY CELLULAR AND MOLECULAR FACTORS ASSOCIATED WITH PROTECTION FROM THE ACQUISITION OF INFECTION. A MANUSCRIPT DESCRIBING THESE FINDINGS IS CURRENTLY IN PREPARATION. IN YEAR 7, BASED ON THE DATA COLLECTED DURING THE PRECEDING YEAR, OUR RESEARCH WILL FOCUS ON EXTENDING CORRELATES OF PROTECTION STUDIES AND CONDUCTING MECHANISTIC ANALYSES TO DEFINE THE CELLULAR SUBSETS AND PATHWAYS UNDERLYING VACCINE-MEDIATED PROTECTION. WE WILL FURTHER CHARACTERIZE INFECTION KINETICS AND IMMUNE RESPONSES TO REPEATED ULTRA-LOW DOSE MTB EXPOSURE MODEL TO BETTER UNDERSTAND HOW LOW-LEVEL MTB EXPOSURE SHAPES HOST IMMUNITY AND SUBSEQUENT INFECTION OUTCOMES. TO PERFORM THESE STUDIES, WE WILL UTILIZE A BARCODED MTB STRAIN TO MONITOR INFECTION DYNAMICS UNDER REPEATED ULTRA-LOW DOSE AEROSOL CHALLENGES. FINALLY, WE WILL ALSO APPLY THIS PHYSIOLOGICALLY RELEVANT CHALLENGE MODEL TO EVALUATE THE PROTECTIVE EFFICACY OF EMERGING TB VACCINES, INCLUDING SUBUNIT MRNA, PROTEIN-BASED, AND LIVE-ATTENUATED VACCINES.”
  • “THIS STATEMENT OF WORK (SOW) OUTLINES THE ACTIVITIES THAT UNIVERSITY OF BETH ISRAEL DEACONESS MEDICAL CENTER (BIDMC) WILL BE PERFORMING. NOTE THAT THE TASK NUMBERS BELOW REFLECT THE NUMBERING OF THE OVERALL ACTIVITIES IN THE PRIME CONTRACT. ALTHOUGH THIS SOW DETAILS THE COMPLETE SUITE OF PROPOSED WORK, THE TASKS ASSOCIATED WITH THIS CONTRACT ITERATION ARE LIMITED TO THE SPECIFIC ACTIVITIES OUTLINED BELOW, DELIVERABLES FOR THIS CONTRACT PERIOD ARE HIGHLIGHTED. YEAR 6 €€Œ BAROUCH OUR RESEARCH PROJECTS IN THE PRECEDING YEARS OF THE AWARD FOCUSED ON DEVELOPING INNOVATIVE MURINE AEROSOL CHALLENGE MODELS FOR THE EVALUATION OF TUBERCULOSIS VACCINES. A RECENT PUBLICATION ESTABLISHED SUBSTANTIAL VACCINE PROTECTION WITH THE LIVE-ATTENUATED ΀�LPRG VACCINE STRAIN IN THE ULTRA LOW-DOSE MURINE AEROSOL CHALLENGE MODEL AS WELL AS THE DEVELOPMENT OF A NOVEL REPEATED ULTRA LOW- DOSE CHALLENGE MODEL THAT LED TO THE IDENTIFICATION OF CORRELATES OF VACCINE PROTECTION. WE OBSERVED THAT THE NOVEL REPEATED ULTRA LOW-DOSE CHALLENGE MODEL RESULTED IN INCREASED STRINGENCY AND REDUCED VACCINE EFFICACY IN TERMS OF PROTECTION FROM DETECTABLE INFECTION AND UNILATERAL INFECTION. IN YEAR 5 WE ESTABLISHED A SECOND-GENERATION MODEL IN WHICH WE FURTHER REDUCED THE CHALLENGE INOCULUM IN ORDER TO PRESERVE A MODEL OF REPEATED EXPOSURE WHILE REDUCING THE STRINGENCY OF CHALLENGE AND IMPROVING THE LIKELIHOOD OF RESOLVING VACCINE EFFICACY. RESEARCH EFFORTS IN YEAR 6 WILL FOCUS ON ASSESSING BCG AND ΀�LPRG VACCINE PROTECTION IN THIS SECOND-GENERATION MODEL IN THE CONTEXT OF A COMPREHENSIVE CORRELATES OF PROTECTION ANALYSIS. RESULTS FROM THE CORRELATES OF PROTECTION ANALYSES WILL BE HYPOTHESIS-GENERATING AND FORM THE BASIS FOR MECHANISTIC STUDIES EVALUATING THE CELLULAR SUBSETS AND PATHWAYS REGULATING VACCINE PROTECTION. THESE STUDIES WILL CONTINUE TO ESTABLISH NEXT-GENERATION MURINE MODELS FOR TB VACCINE TESTING, IDENTIFICATION OF CORRELATES OF PROTECTION, AND MECHANISTIC STUDIES.”
• VANDERBILT UNIVERSITY MEDICAL CENTER

  UEI GYLUH9UXHDX5

  $535K

  Subcontractor to this prime · 1 sub-award · latest Jul 22, 2024

  • Centers for Disease Control and Prevention
  • “IVY 5 - SURVEILLANCE OF ACUTELY ILL ADULTS WITH RESPIRATORY VIRUSES, INCLUDING SARS-COV-2”

No reported sub-awards as a prime contractor.

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.